162 related articles for article (PubMed ID: 31893088)
21. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
Tsuyama N; Sakamoto K; Sakata S; Dobashi A; Takeuchi K
J Clin Exp Hematop; 2017; 57(3):120-142. PubMed ID: 29279550
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.
Morel A; Brière J; Lamant L; Loschi M; Haioun C; Delarue R; Tournilhac O; Bachy E; Sonet A; Amorim S; Laurent C; Gaulard P; Tilly H; Sibon D
Eur J Cancer; 2017 Sep; 83():146-153. PubMed ID: 28735072
[TBL] [Abstract][Full Text] [Related]
23. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
Kim D; Koh Y; Yoon SS
Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
[TBL] [Abstract][Full Text] [Related]
24. Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy.
Shang Z; Zhang Q; Liu W; Wu J; Zhang Y; Xiao Y
Front Oncol; 2023; 13():1242552. PubMed ID: 37849796
[TBL] [Abstract][Full Text] [Related]
25. Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Chen CH; Chen SW; Shen WL; Chen TY; Tsao CJ; Huang WT
Int J Hematol; 2007 Feb; 85(2):105-7. PubMed ID: 17321986
[TBL] [Abstract][Full Text] [Related]
26. The biology and management of systemic anaplastic large cell lymphoma.
Hapgood G; Savage KJ
Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: A case report.
Zhang M; Jin L; Duan YL; Yang J; Huang S; Jin M; Zhu GH; Gao C; Liu Y; Zhang N; Zhou CJ; Gao ZF; Zheng QL; Chen D; Zhang YH
World J Clin Cases; 2021 Jun; 9(17):4268-4278. PubMed ID: 34141790
[TBL] [Abstract][Full Text] [Related]
28. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
29. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
[TBL] [Abstract][Full Text] [Related]
30. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
Koh KN; Im HJ; Suh JK; Lee SW; Choi ES; Seo JJ
Pediatr Blood Cancer; 2015 Jun; 62(6):1063-5. PubMed ID: 25641881
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
Rigaud C; Knörr F; Brugières L; Woessmann W
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101444. PubMed ID: 36907641
[TBL] [Abstract][Full Text] [Related]
33. Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL.
Sun X; Fang X; Jiang Y
Indian J Cancer; 2021; 58(1):108-111. PubMed ID: 33402581
[TBL] [Abstract][Full Text] [Related]
34. ALK-positive anaplastic large cell lymphoma in adults.
Gromowsky MJ; D'Angelo CR; Lunning MA; Armitage JO
Fac Rev; 2023; 12():21. PubMed ID: 37655119
[TBL] [Abstract][Full Text] [Related]
35. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.
Prokoph N; Larose H; Lim MS; Burke GAA; Turner SD
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29601554
[TBL] [Abstract][Full Text] [Related]
36. Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report.
Yang J; Li J; Gu WY; Jin L; Duan YL; Huang S; Zhang M; Wang XS; Liu Y; Zhou CJ; Gao C; Zheng HY; Zhang YH
World J Clin Cases; 2020 May; 8(9):1685-1692. PubMed ID: 32420302
[TBL] [Abstract][Full Text] [Related]
37. [Outcomes of 33 patients with anaplastic large cell lymphoma treated after hematopoietic stem cell transplantation].
Lu N; Li XF; Dong YJ; Wang YN; Fu XR; Wu YM; Li YH; Wang MH; Li NN; Ren HY; Wang Z; Zhang MZ; Wu XX; Hu LD; Liu Y; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):117-122. PubMed ID: 32135627
[No Abstract] [Full Text] [Related]
38. Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.
Shen D; Song H; Zhang J; Liao C; Wang Y; Fang M; Tang Y
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e1-e4. PubMed ID: 33661174
[TBL] [Abstract][Full Text] [Related]
39. Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma.
Verran J; Mathavan V
Case Rep Hematol; 2022; 2022():4749452. PubMed ID: 35154838
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China.
Liu J; Zheng L; Chuang LH
J Med Econ; 2022; 25(1):99-107. PubMed ID: 34927526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
